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The complement system plays an important role in the pathogenesis of rheumatoid
arthritis (RA). Besides driving lectin pathway (LP) activation, the mannan-binding
lectin (MBL)-associated serine proteases (MASPs) also play a key role in regulating
the alternative pathway (AP). We evaluated the effects of N-acetylgalactosamine
(GalNAc)-conjugated MASP-1 and MASP-2 duplexes in vitro and in mice with
and without arthritis to examine whether knockdown of MASP-1 and MASP-2
expression affects the development of arthritis. GalNAc-siRNAs for MASP-1 and
MASP-2 demonstrated robust silencing of MASP-1 or MASP-2 at pM concentrations
in vitro. To evaluate the impact of silencing in arthritic mice, we used the collagen
antibody-induced arthritis (CAIA) mouse model of RA. Mice were injected a 10mg/kg
dose of GalNAc-siRNAs 3x s.q. prior to the induction of CAIA. Liver gene expression
was examined using qRT-PCR, and protein levels were confirmed in the circulation by
sandwich immunoassays andWestern blot. At day 10, CAIA mice separately treated with
MASP-1 and MASP-2 duplexes had a specific reduction in expression of liver MASP-1
(70–95%, p < 0.05) and MASP-2 (90%, p < 0.05) mRNA, respectively. MASP-1-siRNA
treatment resulted in a 95% reduction in levels of MASP-1 protein in circulation with
no effect on MASP-2 levels and clinical disease activity (CDA). In mice injected with
MASP-2 duplex, there was a significant (p < 0.05) 90% decrease in ex vivo C4b
deposition on mannan, with nearly complete elimination of MASP-2 in the circulation.
MASP-2 silencing initially significantly decreased CDA by 60% but subsequently
changed to a 40% decrease vs. control. Unexpectedly, GalNAc-siRNA-mediated
knockdown of MASP-1 and MASP-2 revealed a marked effect of these proteins on
the transcription of FD under normal physiological conditions, whereas LPS-induced
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inflammatory conditions reversed this effect on FD levels. LPS is recognized by Toll-like
receptor 4 (TLR4), we found MBL not only binds to TLR4 an interaction with a Kd
of 907 nM but also upregulated FD expression in differentiated adipocytes. We show
that MASP-2 knockdown impairs the development of RA and that the interrelationship
between proteins of the LP and the AP may extend to the transcriptional modulation of
the FD gene.
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INTRODUCTION
Rheumatoid Arthritis (RA) is a chronic inflammatory
autoimmune disease of the joints, affecting ∼0.24% of the
entire world population (1). The mortality rate for patients with
RA is higher than the general population (2), and the substantial
morbidity of this condition impacts the public health care system
substantially (3). Although new therapeutics have improved
outcomes and quality of life, and more patients will gain access
to new biosimilars, ∼40% patients only respond partially or
not at all to the best of current therapies (4). Furthermore,
disease-modifying anti-rheumatic drugs (DMARDs) ameliorate
the disease but also lead to an increased risk of infections due to
immune suppression (5). Despite clinical improvement afforded
by these therapeutics, the radiological damage in RA can
continue over time due to an underlying inflammatory process
(6) and treatment with anti-TNF antagonists, despite clinical
improvement, has little effect on diagnostic and pathologically
relevant markers like anti-citrullinated protein antibodies
(ACPAs) (7, 8).
Citrullinated peptides are considered a prime example of an
autoantigen in RA, and the presence of ACPAs is significantly
correlated with radiological damage (6). Autoantibodies which
develop against these epitopes, also designated anti-cyclic
citrullinated peptide (CCP) antibodies, can circulate to deposit
in damaged joint tissues, which are rich in citrullinated proteins.
However, the development of ACPA alone is not sufficient
to trigger RA. For example, it has been shown recently that
transgenic (Tg) mice expressing IgM with the V region of
an anti–CCP mAb cloned from a RA patient, thus from a
naturally generated anti-CCP Ab, failed to develop arthritis (9),
a finding consistent with the hypothesis that anti-CCP Abs
alone are not the cause of disease. Rather, a “second hit” has
been postulated to be required for localization of this immune
Abbreviations: CDA, clinical disease activity; AP, alternative pathway; anti-
CCP, anti-cyclic citrullinated peptide; ACPA, anti-citrullinated protein
antibodies; CAIA, collagen antibody-induced arthritis; CP, classical pathway;
LP, lectin pathway; MBL, Mannan-binding lectin; WT, wild type; GalNAc, N-
acetylgalactosamine; ASGPR, Asialoglycoprotein Receptor; rHuC4, recombinant
human complement protein 4; proFD, profactor D; FD, factor D; MASP-1,
mannan-binding lectin-associated serine protease-1; MASP-2, mannan-binding
lectin-associated serine protease-2; MASP-3, mannan-binding lectin-associated
serine protease-3; MAp19, Mannan-binding lectin-associated protein of 19
kDa; MAp44, Mannan-binding lectin-associated protein of 44 kDa [a.k.a
MBL/ficolin/CL-11–associated protein-1, (MAP-1)]; siRNA, small interfering
ribonucleic acid; Luc, Luciferase; mAb, monoclonal antibody; TLR4, Toll-like
Receptor 4; LPS, Lipopolysacchride.
response to the joint (10–12). The nature of this “second hit”
may be quite variable; involving infection or injury and could be
provided by innate immune components, including those of the
complement system.
We and others have extensively probed the role of the
complement protein network in RA pathogenesis to identify
targets within the pathway that are suitable for therapeutic
development (11, 13–18). Inhibition of complement in virtually
every RA mouse model tested leads to decreased disease
progression (12). The evidence for complement’s role in RA
is also evident when examining human patients. Examination
of synovial fluid from RA patients shows the presence of
complement fragments, indicative of complement activation
(19). Blood levels of certain complement activation fragments
are also increased in these patients, while levels of full
length complement proteins may be decreased (20–22). Clinical
trials with complement C5-directed therapeutics such as
PMX53 and Eculizumab have so far been unsuccessful in
the treatment of RA (18). However, these unsuccessful trials
likely reflect the complexity of the complement system and
requirement to also block upstream at C3 activation, or
the relatively late timing of intervention in the disease
course, rather than the lack of a role for complement in
RA pathogenesis.
The complement system is a liver-produced but serum-
effector killing system of the innate immune system. It has now
been recognized to play an important and vital role in many
autoimmune diseases. It exists and functions in each and every
tissue of the body including in the synovium of joints. The
system facilitates clearance of circulating immune complexes,
damaged tissues, apoptotic cells, apoptotic bodies and dead cells
(23, 24), thus possessing strong anti-inflammatory properties for
the benefit of the host, e.g., in the absence of a mature adaptive
immune response. Overall, complement is composed of many
soluble proteins and receptors and is generated in abundance
by the liver (25). Other cells or tissues, however, can secrete
complement proteins, including epithelial and endothelial cells as
well as adipocytes (26, 27). The complement system is activated
by three pathways, i.e., classical pathway (CP), lectin Pathway
(LP) and alternative pathway (AP) (28). All three pathways of
the complement system are activated by different molecules but
converge at the cleavage of C3 and C5, generating C3a, C3b, C5a,
and C5b, via C3 and C5 convertases, respectively. C3a and C5a
function as activators of inflammatory cells via the C3a and
C5a receptors (C5aR) while C5b promotes the assembly of the
membrane attack complex (MAC, C5b–C9).
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The CP consists of C1q, C1r, C1s, as well as C4 and C2,
and the LP consists of pattern recognition molecules (PRMs),
including mannan binding lectin (MBL), ficolins (FCNs) and
Collectins (CLKs), and the effector proteases, MBL-associated
serine proteases (MASPs) MASP-1, -2, and -3. Binding of LP
PRMs to carbohydrates on the surface of microorganisms leads to
MASP-1 autoactivation, MASP-1-mediated activation of MASP-
2, and cleavage of C4 and C2 (29). The CP can’t activate C3
and subsequently the AP amplification loop without C4 (30, 31).
However, the LP can activate C3 and the AP through bypass
routes without the direct involvement C4 or C2 (32). This is only
possible through the direct activation of C3 by LP proteases (33).
The MASP-1 gene encodes three variants via alternative
splicing; two variants are MASP-1 and MASP-3 with different
serine protease domains, and the third variant is MAp44 (a.k.a.
MAP-1), which lacks a serine protease domain (34, 35). Most of
the MASP-1 is produced by the liver (36) and it has been shown
to influence LP activity through direct activation of MASP-2 (37).
The observation that MASP-1/3 cleaves profactor D (proFD) to
mature factor D (FD) has created a paradigm shift regarding
the direct role of LP proteases in also activating the AP of the
complement system (38, 39). Mice lacking MASP-1/3 have no
LP and have suboptimal AP activity (38, 39) and these mice
are resistant to arthritis (40). Of note MASP-1/3−/− mice are
also lean (36) suggesting a link between adipose tissue and
MASPs. Mice lacking MASP-1 have no LP but have intact AP
while mice lacking MASP-3 have no AP but have intact LP
(41). Initially it was shown that in patients with 3MC syndrome,
with combined MASP-1 and MASP-3 deficiency, the AP was
functional while the LP was totally non-functional (37). Later
on it was confirmed both in mice and humans that it is MASP-
3 and not MASP-1 which cleaves proFD (36, 42–45). These
findings were partly confirmed in a 3MC patient lacking only
MASP-3, as it was shown that the majority of FD was present
as proFD. However, this study also highlighted that in humans
minor levels of mature FD are still generated in vivo by a MASP-
3-independent mechanism.MASP-1 is required for AP activation
on certain surfaces, and it was reported that MASP-1 is essential
for LPS-induced but not for zymosan-induced AP activation (46).
Overall, it is now clear that MASP-3 is a major regulator of the
AP. The clinical relevance of inhibition of MASP-3 has recently
been highlighted, as targeted RNAi of MASP-3 in the liver of
mice with MASP-3 duplex attenuated collagen antibody induced
arthritis (CAIA), a mouse model dependent on the AP (36). This
study also showed that rMASP-3 cleaved proFD into mature FD
in vivo inMASP-1/3−/− mice (36).
MBL-associated serine protease-2 (MASP-2) was first
identified using liver cDNA library (47). Later, an alternative
splice variant of MASP-2 was identified as MBL-associated
plasma protein of 19 kDa (MAP19) [a.k.a. MAP-2 or small MAP
(sMAP)] (48). sMAP was cloned and it has the signal peptide
similar to MASP-2 but it has a unique C-terminal sequence
and lacks the serine protease catalytic domain (49). MASP-2
can cleave C4 and C2 (50), while MASP-1 cannot cleave C4 but
can cleave C2 (51). MASP-2 can also activate the AP through a
C4/C2 bypass route that leads to MASP-2-dependent activation
of C3 by an unknown mechanism (30, 52). Thus, in the complete
deficiencies of C4 or C2 this bypass pathway can still activate
the AP as seen in guinea pigs lacking C4 (53) and lupus patients
lacking C2 (54).
Overall, liver predominately generates MASP-1 and MASP-
2 (55), and they can, therefore, be directly targeted by
liver-directed RNA interference (RNAi) mechanisms, such
as asialoglycoprotein receptors (ASGPR)-dependent uptake of
N-acetylegalactosamine (GalNAc)-conjugated small interfering
RNAs (siRNAs) (36). The ASGPR, is conserved between species
expressed on all hepatocytes, and binds the tri-antennary GalNAc
ligand with nanomolar affinity, resulting in internalization of
the receptor and delivery of the GalNAc-conjugated siRNA into
the hepatocyte (56, 57). Liver-directed targeting of MASP-3
by GalNAc-conjugated MASP-3-siRNA significantly attenuated
arthritis by 50% in mice (36). Therefore, for this current
study we used GalNAc-MASP-1-siRNA and GalNAc-MASP-2-
siRNA duplexes targeting hepatocytes to examine their effect
on arthritis.
Our first objective in this study was to generate and test
if GalNAc-conjugated MASP-1 and MASP-2 duplexes silence
MASP-1 and MASP-2. Our second objective was to target liver
MASP-1 or MASP-2 by RNAi and to test their efficacy in vivo in
mice with and without CAIA. Our third objective was to explore
the mechanism(s) by which liver-directed silencing of MASP-1
andMASP-2 effected the LP and AP systemically. In those studies
we found evidence that components of the LP also affect the AP
by regulating the transcription of FD. Our hypothesis is that liver
derived MASP-2 but not MASP-1 provides the “second hit” and
it might be essential for the AP-dependent joint damage, and its
targeted intra-hepatic inhibition can lead to the attenuation of
arthritis by MBL-MASP-2-dependent regulation of FD, which is
predominately generated by adipocytes.
MATERIALS AND METHODS
In vitro Selection of
GalNAc-siRNA-MASP-1 and
GalNAc-siRNA-MASP-2 Duplexes
siRNA sequences were designed based on the available
bioinformatics information to target the MASP-1 splice variant
of the mouse MASP1 gene (22 siRNAs) or the MASP2 gene (46
siRNAs). GalNAc-siRNA conjugates were synthesized using solid
phase synthesis methods as previously described (36, 58).
psiCHECK2-Dual-Glo® Luciferase in vitro
Assay for MASP-1 and MASP-2 Gene
Silencing
The sequence of interest (MASP-1 or MASP-2) was cloned
into the multiple cloning region (XhoI-NotI sites) located
downstream of the Renilla STOP codon in the 3’UTR.
The psiCHECK2-Dual-Glo system enables detection of
siRNA-mediated silencing of target sequences fused to a
Renilla luciferase reporter gene. RNAi-mediated cleavage and
degradation of the fusion mRNA can be measured by a loss
in Renilla signal following siRNA treatment. The psiCHECK2
vector also contains a second reporter gene, Firefly luciferase,
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which is driven by a different promoter and allows for
normalization of Renilla expression. An African Green monkey
Cos-7 cell line was used in vitro to examine the effect of MASP-1
and MASP-2 siRNA duplexes on the expression of MASP-1
and MASP-2 in the psiCHECK2 system. All transfections were
repeated for a total of three times. Inhibitory Concentration
(IC50) of each MASP-1 or MASP-2 duplexes were calculated
from the expression curve and is included on the plots.
Selection of the Active GalNAc-MASP-1
and GalNAc-MASP-2 siRNA Duplexes
in vivo
The effect of MASP-1 and MASP-2 duplexes on MASP1 and
MASP2 expression was initially characterized in 8 weeks old
C57BL/6J mice (Charles River Laboratories). Single doses of 10
mg/kg of MASP-1 and of MASP-2 duplexes were administered
via a subcutaneous injection. Livers were harvested on Day
7 post s.q. injection. mRNA was isolated using RNeasy 96
Universal tissue kit (Qiagen). High-Capacity cDNA Reverse
Transcription Kit (Applied Biosystems) was used to convert the
mRNA samples into cDNA. Levels of MASP-1 and MASP-2
expression were analyzed using qRT-PCR reagents compatible
with Roche Lightcycler 480 based on previously published studies
(36). The MASP-1 and MASP-2 mRNAs were measured using a
customized TaqMan assay (ThermoFisher) and normalized to the
endogenous GAPDH expression (ThermoFisher).
Effect of GalNAc-MASP-1 and
GalNAc-MASP-2 Duplexes on Induction of
Collagen Antibody-Induced Arthritis in
Mice
WT mice were injected s.q. with 10 mg/kg on days −10, −5,
and on day 0 either with GalNAc-Luciferase-siRNA (n = 10) or
GalNac-MASP-1 (n = 10) or with GalNAc-MASP-2-siRNA (n
= 10). Then CAIA was induced in these WT mice by using a
mixture of 5 mAb to bovine collagen type II (CII) (Arthrogen-
CIA, Chondrex) according to published studies (59–61). All WT
mice received i.p., injections of 8mg of Arthrogen on day 0
and 50µg of LPS from E. coli strain 0111B4 on day 3. All mice
were sacrificed at day 10 post anti-collagen antibodies injection.
The total duration of the CAIA experiment was day 20 post
the first siRNA injection. The clinical disease activity (CDA)
in all groups of WT mice was determined every day by two
trained laboratory personnel acting independently and blinded
as to treatment according to our previously published methods
(36, 40, 61, 62).
qRT PCR to Measure Liver Expressed
MASPs in Mice With and Without Disease
Mouse liver from first cohort of WT mice (n = 30) injected
(s.q.) with GalNac-Luciferase (n= 10), GalNAc-MASP-1 (n= 10)
and GalNAc-MASP-2 (n = 10) siRNAs with disease, sacrificed
at day 20, were homogenized using a bullet blender (36). The
expression ofMASP-1 andMASP-2 weremeasured from the liver
by qRT-PCR in a blinded fashion. Similarly, in a second cohort,
liver from WT mice (n = 34) treated with GalNAc-conjugated
Luciferase siRNA (n= 8) or with MASP-1 siRNA (n= 8) or with
MASP-2 siRNA (n = 9) or with MASP-1 plus MASP-2 siRNAs
(n = 9) without disease were processed for RNA extraction. In
this study, out of 34 mice, LPS (50 µg/mouse/i.p.) was injected,
at day 10, in mice treated with GalNAc-conjugated Luciferase
siRNA (n = 4) or with MASP-1 siRNA (n = 4) or with MASP-
2 siRNA (n = 5) or with MASP-1 plus MASP-2 siRNAs (n = 5)
and these mice were sacrificed at day 14. The remaining 16 mice,
i.e., 4 mice per treatment group, were not injected with LPS
and sacrificed at day 25. Total RNA from the liver was isolated
from the liver homogenates using RNAeasy Mini kit (Qiagen
Inc., Germantown, MD). 18S ribosomal RNA (18S rRNA) was
used as an internal control in each experiment and all data were
expressed in pg/ng mRNA/18S RNA. All mRNA samples were
analyzed in duplicate. All sample were analyzed by amplifying
at 40 cycles according to the methods published previously in
Nature Protocols (14, 63). All qRT-PCR data were analyzed by
using cDNA based on the standard curve made by using liver
RNA from a normal WT mice.
Time-Resolved Immunofluorometric Assay
to Measure MASP-1 Protein
The absolute levels of MASP-1 protein were measured by
using Time-resolved immunofluorometric assay (TRIFMA), a
sandwich-type immunoassay using europium-labeled detecting
agents as described (64). In this method, the concentrations of
MASP-1 protein in the sera fromWTmice injected with GalNAc-
Lucifease-siRNA or GalNAc-MASP-1-siRNA or GalNAc-MASP-
2-siRNA were determined by using microtiter wells coated
with monoclonal anti-mouse MASP-1 antibody, followed by
incubation with samples and detection using biotinylated anti-
MASP-1 antibody and subsequently by adding Eu3+-conjugated
streptavidin and reading of signal by time-resolved flourometri
(Perkin Elmer, Hvidovre, Denmark) (64).
C4b Deposition on Mannan Particles Using
Mouse Serum
To assess the functionality of the LP, a 96-well ELISA Costar
plates was pre-coated with 9 ug/ml of mannan diluted in 0.05M
Sodium carbonate buffer, pH 9.5 for overnight at 4◦C. The ELISA
plates were flipped gently with no wash followed by blocking with
1% BSA 1xPBS (with Ca2+ Mg2+) for 1 h at room temperature.
After washing 3x with 1xPBS 0.05% Tween 20, 100 µl of 10%
serum diluted in MBL binding buffer [20mM Tris, 1M NaCl,
0.05 % (v/v) Triton X-100, 10mM CaCl2, 15mMNaN3, 1 mg/ml
HSA, pH 7. 4] was added to each well in duplicate, and the
ELISA plates were left at 4◦C overnight. Serum was subsequently
removed by washing, and recombinant human C4 (rHuC4)
protein (Complement Technology Inc., Tyler, Texas) diluted in
sodium barbital buffer was added to the wells. One percent sera
from WT and MASP-2−/− mice were used as a positive and
negative controls, respectively. No target control contained no
rHuC4. ELISA plates were incubated for 1.5 h at 37◦C followed by
3x washings with 1xPBS 0.05% T20 (with Ca2+ Mg2+). After 1 h
anti-C4C biotinylated antibody (1µg/ml) diluted in 1xPBS 0.05%
T20 (with Ca2+ Mg2+) and incubated at room temperature for
2 h. One hundred microliter of Streptavidin (dilution 1:1,000)
was added to each well after washing three times (with Ca2+
Mg2+). The ELISA plates were developed using 100 µl of
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1:1 diluted Super SignalTM West Pico Plus Chemiluminescent
Substrate (Thermo Scientific, Rockford, IL). The reaction was
stopped using 50 µl with 2N H2SO4 and absorbance read at
450 nm, correcting for background at 550 nm.
Western Blot Analysis for MASP-2
To detect the presence or absence of MASP-2 protein, before,
during and after MASP-2 silencing, by Western blot analysis,
a total of 40µL of D-Mannose-Agarose beads (resin) (Sigma)
were equilibrated in wash buffer containing TBS, 5mM CaCl2 +
1mM Pefabloc SC (Sigma, 76307). Ten µL of serum was mixed
with 20µL of wash buffer, added to the resin, and incubated
for 1.5 h. The beads were washed three times, re-suspended
in 50 µL of wash buffer, and transferred to Pierce Microspin
column (Thermo Scientific). The spin columns were centrifuged
for 2min at 4,000× g, until the resin become dry. Elution of
MBL-MASP-2 complexes was performed by adding 30µL of
electrophoresis sample buffer to each tube [7.5µL of NuPAGE
LDS sample buffer (Life technologies, NP0007)+ 3µL NuPAGE
reducing agent (Life technologies, NP0009)+ 19.5µL of ddH2O]
and centrifuging the resin until it is dry. Then 30 µL of the eluate
was heated at 80◦C for 5min and loaded on the 10% SDS gel
using 1xMOPS (Invitrogen) and 1xNupage (Invitrogen) running
buffer. Proteins were transferred to a PVDF membrane using
1xNupage tran (Invitrogen) transfer buffer, and the membrane
was blocked in PBS + 5% milk for 2 h. The blot was incubated
with a primary antibody, biotinylated monoclonal Rat anti-
human MASP-2/MAp19 (1µg/ml) (6G12, cross reacting with
mouse MASP-2) in PBS + 5% milk and then incubated at 4◦C
overnight (65). HRP-conjugated Streptavidin (diluted 1:1,000)
was used as a secondary antibody. Finally, the blot was developed
by incubating with 12mL of SuperSignal West Pico PLUS
Chemiluminescent Substrate (ThermoFisher) for 10min. The
blot was scanned using Genegnome XRQ Chemiluminescence
Imaging System and Gene Tool analysis software from Syngene
(Frederick, MD), and the density of each band was quantified
using the Quantity One R© software (Bio-Rad, Hercules, CA).
Measurement of Expression of AP
Complement Components in Liver After
Silencing of MASPs and LPS Treatment
We measured, by qRT PCR, the expression of complement
C3, factor B (FB), factor D (FD), Properdin, C5, MASP-1,
MASP-2, and MASP-3 from the liver of mice treated with
GalNAc-Luciferase siRNA, GalNAc-MASP-1 siRNA, GalNAc-
MASP-2 siRNA, andGalNAc-MASP-1 plusMASP-2 siRNAs. The
expression of the above-mentioned complement components
were measured according to our published methods (14, 36).
Western Blots for FD Protein
To determine the increase or decrease in FD protein in the
circulation of WT mice, with and without LPS, after silencing
with GalNAc-MASP-1/MASP-2 duplexes simultaneously,
Western blots for FD were performed according to our published
methods (36, 40).
Determination of the Binding Affinity
Between TLR4 and MBL Using Microscale
Thermophoresis
Recombinant Human TLR4 (R&D Systems) was re-suspended
in a buffer containing 20mM Tris-HCl pH 7.5, 150mM NaCl,
5mM CaCl2, and 1mM BME. TLR4 was fluorescently labeled
using the NanoTemper Monolith His-Tag Labeling Kit RED-
tris-NTA 2nd Generation kit (MO-L018) per the manufacturer’s
protocol. TLR4 was titrated with recombinant MBL (clinical
grade) with concentrations varying from 20.8µM to 635 pM,
while keeping the labeled TLR4 at 5 nM. Samples were loaded
into standard capillaries, and Microscale thermophoresis (MST)
experiments were carried out using a Monolith NT.115 pico
(NanoTemper Technologies GmbH, Munich, Germany). The
thermophoresis was monitored at 20% LED power and highMST
power. Data were analyzed and fit to the Kd model using MO.
Affinity software (version 2.3) (NanoTempet Technologies, CA)
in duplicate.
Determine Expression of TLR4 and FD in
3T3 Cell Line and Adipocytes
To detect TLR4 on the cell surface of cells by flow cytometry,
PE-conjugated mouse anti-TLR4 antibody (CD284) (Biolegend)
was used along with matched isotype control, rat IgG2a k
PE-conjugated (BioLegend). Primary adipocytes derived from
adipose tissue of C57BL6 mice were also examined by flow
cytometry. The Mouse 3T3 L1 embryonic cell line was used
to examine the expression of TLR4 receptors and FD by qRT
PCR as mentioned above. 3T3L1 cells were cultured based on
our previously published study (66). 3T3L1 cell line was used as
analogous to adipocytes as these cells differentiate into adipocyte-
like morphology under certain conditions (66). Differentiated
3T3L1 cells were also stimulated with various doses of LPS (E.
coli) (1.25 or 2.50 or 5µg/ml) or with recombinant human
MBL (10 or 20µg/ml) for 48 h to determine their effect on the
expression of FD and TLR4.
Statistics
Some of the TRIFMA data were analyzed by using the Excel
program. Analysis of variance (ANOVA) was used to comparing
more than two independent groups. Two-tailed Student’s t-test
was used to find out the differences between two means. DATA
were expressed as standard error of the mean (SEM). The level of
significance was defined as p < 0.05.
RESULTS
IC50 of GalNAc-MASP-1 and
MASP-2-siRNA Duplexes
In vitro screening led to the selection of one duplex each of
GalNAc-MASP-1 (IC50 = 0.0027 nM) and MASP-2 (IC50 =
0.1042 nM) (Figures 1A,B) siRNA. GalNAc-MASP-1-siRNA or
GalNAc-MASP-2-siRNA were both 23 bp duplexes. The duplex
of GalNAc-MASP-2-siRNA have no off-target effect on MASP-1,
and vice versa, as shown below (Figure 4).
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FIGURE 1 | IC50 for MASP-1 and MASP-2 silencing with GalNAc-MASP1 or GalNAc-MASP-2 siRNAs: A Dual-Glo luciferase assay was performed using COS7 cells
expressing individually Firefly Luciferase-MASP1 or MASP2 fusion constructs. COS7 cells were transfected with mouse MASP-1 or mouse MASP-2 specific siRNAs at
the concentrations indicated. Luminescence levels were measured at 48 hrs post transfection with siRNAs. The ratio of normalized luminescence was plotted in MS
Excel to calculate the IC50 for MASP-1 and MASP-2 duplexes— (A) MASP-1 duplex IC50 = 0.0027 nM, (B) MASP-2 duplex IC50 = 0.1042 nM.
FIGURE 2 | Comparing levels of (A) MASP-1 and (B) MASP-2 expression by
qRT-PCR in C57Bl/6J mice liver. Liver mRNA was extracted at day 7 after
mice were injected with either GalNAc–MASP-1–siRNA or
GalNAc-MASP2-siRNA or PBS. Gene expression was examined using
qRT-PCR. GAPDH expression was used as an internal control to calculate the
expression of MASP-1 or MASP-2. Data shown as mean and SEM of three
replicates. The p-values were calculated using t-test. *p < 0.05 vs. PBS.
GalNAc-MASP-1 and MASP-2 Duplexes
Silenced MASP-1 and MASP-2 Expression
in the Liver of Mice Without Disease
To determine the in vivo efficacy of GalNAc-MASP-1-siRNA
and GalNAc-MASP-2-siRNA duplexes on the expression
of MASP-1 and MASP-2, healthy C57Bl/6 mice were
used (Figure 2). In this experiment, mice were injected
with a single dose (10 mg/kg) of either PBS or GalNAc-
MASP-1-siRNA or GalNac-MASP-2-siRNA duplexes
on day 0 and sacrificed at day 7. A robust silencing
in the siRNA-treated groups was observed, i.e., 93% of
MASP-1 (Figure 2A) and 69% of MASP-2 (Figure 2B)
expression was silenced after a single subcutaneous
administration. Initially 58% decrease in MASP-3 expression
was also noticed with silencing of MASP-1 but none with
MASP-2 silencing.
GalNAc-MASP-2-siRNA Partially
Attenuated Clinical Disease in Mice With
CAIA
To examine the systemic effect of GalNAc-MASP-1-siRNA
and GalNAc-MASP-2-siRNA on arthritis, mice were injected
(s.q.) three times with GalNAc-Luciferase, GalNAc-MASP-1-
siRNA, or GalNAc-MASP-2 siRNA before the induction of
disease. All mice injected with anti-CII mAb and LPS developed
disease after day 3. At day 10, the CDA in mice injected
with GalNAc-Luciferase, GalNAc-MASP-1, or GalNAc-MASP-
2 duplexes were 10.7 ± 0.597, 7.7 ± 1.57, and 6.4 ± 1.44,
respectively (Figure 3A). In mice treated with GalNAc-MASP-
1-siRNA, there was a significant 35% decrease (p < 0.030)
in the CDA at day 7, whereas there was no difference at
day 10 (Figure 3A). However, in mice treated with GalNAc-
MASP-2 siRNA there was from day 5 to 10 a consistent
decrease in the CDA. At day 10, there was a significant
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FIGURE 3 | Partial decrease in the clinical disease activity in WT mice treated with GalNAc-MASP-2-siRNA but not with GalNAc-MASP-1 duplex.
GalNAc-Luciferase-siRNA was used as negative control compared to GalNAc-MASP-1-siRNA or GalNAc-MASP-2-siRNA. Arthritis, in C57BL/6 mice, was induced by
injecting a mixture of five anti-collagen monoclonal antibodies as described in the Methods. WT mice were injected three times s.q with Luciferase siRNAs as a
negative control or with GalNAc-MASP-1-siRNA or GalNAc-MASP-2-siRNA at day −10, 0 and at day 3. Disease in mice was checked from day 4 to 10. (A) CDA in
mice treated with GalNAc-Luciferase-siRNA or GalNAc-MASP-1-siRNA or GalNAc-MASP-2-siRNA. (B) Prevalence (%) of disease, in mice treated with
GalNAc-Luciferase-siRNA or GalNAc-MASP-1-siRNA or GalNAc-MASP-2-siRNA. (C) Change in weight (%) in mice treated with GalNAc-Luciferase-siRNA or
GalNAc-MASP-1-siRNA or GalNAc-MASP-2-siRNA. Data shown represent the mean ± SEM based on WT mice injected s.q. with GalNAc-Luciferase-siRNA, n = 30
and with GalNAc-MASP-1-siRNA (n = 10), GalNAc-MASP-2-siRNA (n = 10). *p < 0.05 in comparison to mice to GalNAc-Luciferase-siRNA injected mice (n = 10).
(p < 0.013) 40% decrease in the CDA of mice treated with
GalNAc-MASP-2-siRNA compared with GalNAc-luciferase, and
at day 7 there was a significant (p < 0.0003) 60% decrease
in the CDA in mice treated with GalNAc-MASP-2 siRNA
compared with the mice treated with GalNAc-Luciferase-
siRNA (Figure 3A).
The prevalence of disease at day 10 in WT mice injected
with GalNAc-Luciferase, GalNAc-MASP-1 and GalNAc-MASP-2
duplexes was 100, 100, and 90%, respectively (Figure 3B). There
was no significant (p < 0.68) and (p < 0.88) effect on the weights
of mice treated with GaLNAc-MASP-1 and GalNAc-MASP-2
siRNA throughout the study (Figure 3C). No toxicity was seen,
and no mouse died during the course of this experiment. Overall
these data suggest that GalNAc-MASP-2, but not GalNAc-MASP-
1 partially attenuated CAIA in mice.
Robust Downregulation of MASP-1 Protein
by Liver-Specific RNAi Targeting With
GalNAc-MASP-1 Duplex in Mice With CAIA
A sandwich type immunoassay, i.e., a Time-resolved
immunofluorometric assay (TRIFMA) to measure the absolute
levels of MASP-1 was used in the sera from mice from the CAIA
model (Figure 4). MASP-1 protein levels were measured at
baseline (−day 10 relative to disease induction with anti-CII
mAbs), after three injections of siRNA (day 0) and after the
induction of disease (at day 10) (Figures 4A–C). The levels
of MASP-1 were significantly (p < 0.0001) decreased by 95%
in mice after three injections with GalNAc-MASP-1 siRNA,
relative to the mice injected with the GalNAc-Luciferase siRNA,
before the development of disease (day 0) and at the end of the
study (day 10). (Figures 4A–C). In mice injected with control
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FIGURE 4 | Time-resolved immunoflorometric assay for MASP-1 levels
showing a decrease in the absolute levels of MASP-1 protein in the circulation
of mice arthritic injected with GalNAc-MASP-1-siRNA. Sera were diluted 1:75
from arthritic mice treated with GalNAc-Luciferase-siRNA,
GalNAc-MASP-1-siRNA and GalNAc-MASP-2-siRNA and levels of MASP-1
were examined by ELISA. (A) No change in MASP-1 levels at day −10, 0 and
at day +10 treated with control GalNAc-Luciferase-siRNA. (B) A substantial
decrease in the levels of MASP-1 at day 0 and at day +10 vs. −10 in the
circulation of mice treated with GalNAc-MASP-1-siRNA. (C) No decrease in
the levels of MASP-1 at day 0 and at day +10 vs. −10 in the circulation of
mice treated with GalNAc-MASP-1-siRNA. Data from all mice (n = 30) have
been shown. p < 0.05 at day 0 and at day +10 vs. at −10 mice injected with
GalNAc-Luciferase-siRNA (n = 10) or GalNAc-MASP-1-siRNA (n = 10) or
GalNAc-MASP-2-siRNA (n = 10).
GalNAc-Luciferase-siRNA or GalNAc-MASP-2-siRNA there
was no effect on MASP-1 levels (Figures 4A,C). These data
show that MASP-1 duplex specifically and significantly silenced
MASP-1 levels systemically for a long time not only before
the development of arthritis but even after the development
of arthritis. Despite the robust suppression of MASP-1 level,
MASP-1 does not play a significant role in the pathogenesis
of CAIA, because mice treated with GalNAc-MASP-1-siRNA
were not protected as compared to mice treated with control
GalNac-Luciferase siRNA (Figure 3A).
Complete Elimination of MASP-2 Protein
by Western Blot Analysis After Liver
Targeted RNAi MASP-2 Silencing in Mice
With CAIA
Western blot analysis for MASP-2 protein was done to examine
the effect on MASP-2 on MASP-1 silencing by GalNAc-MASP-
2-siRNA on circulating protein levels (Figure 5). Sera from a
subset of mice evaluated in the CAIA model were examined by
western blot (Figure 5A). We found that there was no effect
on MASP-2 levels in the sera from each mouse injected with
GalNAc-Luciferase-siRNA (Figure 5A, lanes 2, 3, 4) or GalNAc-
MASP-1-siRNA (Figure 5A, lanes 5, 6, 7). A distinct band of
∼75 kDa of MASP-2 was present along with ∼19kDa MAp19
(Figure 5A, lanes 2–8 and 11, lane 1, marker). These MASP-
2 or MAp19 bands were present only in the sera from mice
before treatment GalNAc-MASP-2-siRNA (day −10; Figure 5A,
lane 8) but completely absent or barely visible after treatment
with GalNAc-MASP-2-siRNA (day 0; Figure 5A, lane 9) and
after disease development (day 10; Figure 5A, lane 10). Identical
results were seen using serum from another mouse (Figure 5A,
lanes 11, 12, 13). Sera from FD−/− and MASP-2−/− mice
were used as positive and negative controls, respectively, to
show the specificity of Western blot analysis for MASP-2
protein (Figure 5B, lanes 1, 2). MASP-2 protein is absent in
serum from MASP-2−/− mouse (Figure 5B, lane 1) as expected
but present in the serum from FD−/− mouse (Figure 5B,
lane 2). These data show that liver targeting of MASP-2 by
GalNAc-MASP-2-siRNA was highly effective, and this effect
lasted systemically for at least 10 days after the last siRNA
dose. Our data once again confirmed that most of the MASP-
2 in the circulation is generated by the liver and it can be
inhibited below threshold detection levels even during acute
inflammation (Figure 5).
Liver-Targeted RNAi With GalNac-MASP-2
Duplex Robustly Silences C4b Deposition
by the LP
To examine the functionality of MASP-2 silencing in liver
by GalNAc-MASP-2-siRNA, C4b deposition via MBL pathway
of the complement on mannancoated microtiter well surfaces
was measured by ELISA. This procedure specifically excluded
the activation from the CP due to the buffer composition,
i.e., no C1q binding occurs to the surface. There is sufficient
MASP-1 to activate MASP-2 in GalNac-MASP-1-siRNA treated
mice. Sera from mice treated with a single dose of GalNAc-
Luciferase-siRNA, GalNAc-MASP-1-siRNA, or GalNAc-MASP-
2-siRNA were added to ELISA plates pre-coated with mannan
(Figures 6A–C). There was a complete and significant inhibition
of C4b deposition both before and after the induction of disease
(p < 0.05) in the sera from mice injected with GalNAc-MASP-
2-siRNA (Figure 6C). These data were remarkably consistent
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FIGURE 5 | (A) Western blot analysis showing nearly complete elimination of MASP-2 in the circulation of WT arthritic mice treated with GalNAc-MASP-2-siRNA.
MASP-2 protein from arthritis mice before (day –day 10) and after treatment and before disease induction (day 0) and after disease induction (day +10) was pulled out
by using D-Mannose-Agarose beads as mentioned in the Materials and Methods. The primary detection antibody biotinylated Rat anti-human MASP-2/MAp19 (6G12)
and secondary antibody HRP-conjugated Streptavidin were used, respectively. Complete absence of MASP-2 (∼75 kDa) in the circulation of WT mice treated with
GalNAc-MASP-2-siRNA at day 0 and at day +10 (lanes 12, 13). Presence of MASP-2 prior to the treatment with GalNAc-MASP-2 and prior to the disease induction
(lane 11). Repeat data from another mouse treated identically with GalNAc-MASP-2-siRNA (lanes 8, 9, and 10). Presence of MASP-2 in the circulation of mice treated
with GalNAc-MASP-1-siRNA at day −10, at 0 and at +10 (lanes 5, 6, and 7). Presence of MASP-2 in the circulation of mice treated identically with control
GalNAc-Luciferase-siRNA at day −10, at 0 and at +10 (lanes 2, 3, and 4). Lane 1 (protein marker). A band of MAp19 (a.k.a. sMAP) (19 kDa) was also seen in the sera
from mice (lanes 2–8 and 11). Sera from MASP-2−/− and FD−/− mice with no disease were used a negative and positive controls, respectively (B lanes 1 and 2).
Representative data from GalNAc-Luciferase-siRNA (n = 1) or GalNAc-MASP-1-siRNA (n = 1) or GalNAc-MASP-2-siRNA (n =2) treated mice have been shown.
Western blot were repeated 2x with identical results.
in all mice (10 out of 10) treated with GalNAc-MASP-2-siRNA
(Figure 6C). On the other hand, there was no significant effect
on C4b deposition from mice treated identically with GalNAc-
Luciferase-siRNA or GalNAc-MASP-1-siRNA neither before nor
after induction of disease (Figures 6A,B). Overall, these data
show that liver-targeted MASP-2 silencing by GalNAc-MASP-
2-siRNA completely abrogated C4b deposition (10 out of 10
mice) in the circulation and indicated that most of the MASP-
2 is generated by the liver (Figure 6C). Furthermore, MASP-
2 duplexes functionally impaired the lectin pathway of the
complement. There was no significant off-target effect on C4b
deposition of GalNAc-Luciferase-siRNA or GalNAc-MASP-1-
siRNA (Figure 6).
GalNAc-MASP-1 and MASP-2 Duplexes
Silenced MASP-1 and MASP-2 Expression
in the Liver Mice With Disease
Liver expression of MASP-1 and MASP-2 mRNA was examined
in mice from the CAIA model. qRT PCR data from the liver
of these mice at day 10 confirmed that there was a significant
(p < 0.05) decrease in the expression of MASP-1 (70–95%) and
MASP-2 (90%) with no off target effect on each other (Figure 7).
However, in there was a decrease (58%) in expression of MASP-3
in the liver from normal mice with arthritis treated with GalNAc-
MASP-1-siRNA (data not shown) but not with GalNAc-MASP-2-
siRNA (data not shown). Later on we have not seen any effect on
MASP-3 under normal physiological or mild pro-inflammatory
conditions (Figure 8C). These data were analyzed in a blinded
fashion using two different probes and primers by qRT PCR and
results were identical.
Effect on the Expression of Alternative
Pathway Components in Liver After
Targeted RNAi Silencing of Individual and
Combined MASP-1 and MASP-2 Genes
To examine the individual and combined effects of MASP-1 or
MASP-2 duplexes on the AP components mice were injected
again three times (at day −10, −5, and at day 0) with a single
dose (10mg/kg) of GalNAc-Luciferase-siRNAorGalNAc-MASP-
1 siRNA or GalNAc-MASP-2 or GalNAc-MASP-1 + MASP-2
–siRNAs. No disease was induced in these mice but a single dose
of LPS was injected at day 10 to generate mile pro-inflammatory
conditions. No significant differences in the liver were seen in the
expression of C3, FB, and C5 (Figure 8). Surprisingly a significant
(p < 0.05) decrease of 72% was seen in the liver expression of
FD, in mice without injection of LPS, after combined silencing
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FIGURE 6 | ELISA showing a large decrease in C4b deposition on mannan in
the sera from arthritic mice treated three times with GalNAc-MASP-2-siRNA
but not with GalNAc-MASP-1-siRNA or GalNAc-Luciferase-siRNA. Sera from
mice treated with MASPs or control siRNAs as mentioned above were diluted
1/500 in a tris/high salt/calcium buffer (inhibit any activation by the classical or
the MBL pathway) examined at day-10 (before siRNAs injection & before
disease induction), day 0 (after injection but before disease induction) and at
day 10 (after disease induction). Human recombinant C4 protein was used to
show the cleavage into C4b by MASP-2 (mouse MASP-2 bound as
MBL/MASP-2 complexes onto the mannan efficiently cleaves human C4—and
C4b becomes bound) followed by detection with anti-C4 antibody as
mentioned in the Materials and Methods. No change in C4b deposition in the
sera from arthritic mice treated with (A) GalNAc-Luciferase-siRNA (B)
GalNAc-MASP-1-siRNA. (C) A substantial decrease in C4b deposition in the
sera from mice treated GalNAc-MASP-2-siRNA. Data from all individual mice
treated with GalNAc-Luciferase-siRNA (n = 10) or GalNAc-MASP-1-siRNA (n
=10) or GalNAc-MASP-2-siRNA (n =10) have been shown. p < 0.05 at day 0
and at day +10 vs. at −10 mice injected GalNAc-Luciferase-siRNA,
GalNAc-MASP-1-siRNA and GalNAc-MASP-2-siRNA.
of MASP-1 and MASP-2 (Figure 8F). This reduction in FD
expression was reversed in mice injected with LPS (Figure 8F).
MASP-2 silencing alone resulted in a reduction of FD mRNA in
FIGURE 7 | Quantitative RT-PCR analysis of MASP-1 and MASP-2 expression
from the liver of WT arthritic mice injected with GalNAc-Luciferase-siRNA or
GalNAc-MASP-1-siRNA or GalNAc-MASP-2-siRNA duplexes (n = 10 per
group). Total RNA was extracted at day 10 from the liver of mice injected s.q.
with multiple doses of GalNAc-MASP-1-siRNA or GalNAc-MASP-2-siRNA
duplexes. MASP-1, MASP-2, and MASP-3 expression was examined using
qRT-PCR. Liver from WT mouse was used as a positive control. Endogenous
GAPDH mRNA expression was used as an internal control to normalize the
expression of MASP-1 and MASP-2. *p < 0.05 vs. mice injected with
GalNAc-Luciferase-siRNA.
LPS treated mice (Figure 8F). LPS induced mild inflammatory
response as confirmed by slightly enhanced expression of IL-
1β and TNF-α cytokines (Figures 9A,B). The expression of
Properdin was also significantly (p < 0.05) increased in the liver
of mice injected with GalNAc-Luciferase-siRNA followed by an
injection of LPS but not without LPS (Figure 8G). The decrease
in FD expression in the liver show that MASP-1 and MASP-2
together or MASP-2 alone might be regulating the transcription
of FD in adipocytes present in the liver in a steady state, but
during inflammation this regulating capacity might be lost or
switched to something else.
FD Levels in the Circulation Increase After
Simultaneously Silencing of
MASP-1/MASP-2 in Response to the LPS
Western blot data show that there was qualitative increase
in the levels of FD in the circulation of mice injected with
LPS after silencing of both MASP-1/MASP-2 simultaneously,
in contrast to the mice without injection of LPS (Figure 10).
These data were consistent in six different mice injected with
no LPS or with LPS after silencing both MASP-1/MASP-2
genes (Figure 10, lane 3 vs. 4; lane 5 vs. 6 and lane 7 vs.
8). Nonetheless there was variability (4 to 67%) regarding an
increase in the levels of FD in the circulation of mice after
silencing MASP-1/MASP-2 simultaneously (Figure 10). Again
these FDWestern blot data in the circulation confirms themRNA
expression data in the liver that combined silencing of MASP-
1 and MASP-1 in the liver also effected the FD protein levels in
the circulation.
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FIGURE 8 | Effect of a long-term silencing of MASP-1 and MASP-2, in vivo with no disease, on expression of various AP complement components induced by LPS.
The expression of AP complement components was measured by qRT-PCR. WT mice were injected with three doses of GalNAc-Luciferase-siRNA,
GalNAc-MASP-1-siRNA, GalNAc-MASP-2-siRNA and GalNAc-MASP-1+MASP-2-siRNAs. At day 10, 3 mice from each group were injected with LPS and sacrificed
at day 17 and 2 non-injected control mice were sacrificed at day 25. Liver from all mice examined for the expression of MASP-1, MASP-2, MASP-3, C3, FB, FD,
Properdin, and C5. (A) MASP-1 (B) MASP-2 (C) MASP-3. (D) C3 (E) FB, (F) FD, (G) Properdin, and (H) C5. 18S rRNA was used as internal control and the values
have been shown in pg/ng 18S rRNA. *p < 0.05 compared with mice treated with or without LPS. Liver from mice treated with or without LPS were cut into three
pieces and the expression of complement components was examined separately and repeated two times from each piece. Total mice used in this study were 34 i.e.,
GalNAc-Luciferase-siRNA (n = 8), GalNAc-MASP-1-siRNA (n = 8), GalNAc-MASP-2-siRNA (n = 9) and GalNAc-MASP-1+MASP-2-siRNAs (n = 9). Data are
expressed as Mean ± SEM *p <0.05 considered significant.
FIGURE 9 | Effect of LPS on inflammatory cytokines after a long term silencing of MASPs. The expression of IL-1β and TNF-α cytokines, in liver, were measured by
qRT-PCR. WT mice were injected three times with a single dose of GalNAc-Luciferase-siRNA, GalNAc-MASP-1-siRNA, GalNAc-MASP-2-siRNA and
GalNAc-MASP-1+MASP-2-siRNAs followed by an injection of LPS or no LPS injection. Total mice used in this study were 34 i.e., GalNAc-Luciferase-siRNA followed
by LPS (n = 4) or no LPS (n = 4), GalNAc-MASP-1-siRNA followed by LPS (n = 4) or no LPS (n = 4), GalNAc-MASP-2-siRNA LPS (n = 4) or no LPS (n = 5) and
GalNAc-MASP-1+MASP-2-siRNAs LPS (n = 4) or no LPS (n = 5). Data are expressed as Mean ± SEM. *p < 0.05 considered significant.
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FIGURE 10 | Western blot analysis for FD in serum showing the effect of
simultaneously silencing of MASP-1/MASP-2 genes in WT mice followed by
treatment with or without LPS. Sera from FD−/− and WT mice were used as a
negative and positive controls, respectively (lanes 1 and 2). Sera from WT mice
with no treatment or with treatment with LPS (lanes 3 vs. 4); (lanes 5 vs. 6) and
(lanes 7 vs. 8) after MASP-1/MASP-2 silencing have been shown. The original
Western blot was cut to show the actual results for FD. A band of FD ∼26 kDa
shows the presence of FD. Data from six mice have been shown.
Binding Affinity of MBL to TLR4 by
Microscale Thermophoresis
MBL has been previously shown to interact with TLR4 (67, 68),
we sought to determine whether the effects of silencing might be
through this pathway. In order to confirm the reported binding
of MBL to TLR4, MST experiments were carried out. Human
TLR4 was fluorescently labeled and titrated against varying
concentrations of MBL (Figure 11). All MST traces appeared
normal and there was no aggregation (data not shown). The final
Kd for the binding was determined to be 907.28 ± 262.77 nM
(Figure 11). Thus, we confirm that MBL binds TLR4 directly.
Expression of TLR4 and FD and in 3T3
Cells and Adipocytes
To further understand the interaction between lectin pathway
components with LPS activation, we examined the interaction
between MBL and TLR4. By flow cytometry, after several
repetitions, we found no distinct expression of TLR4 receptors
on the surface of 3T3L1 cells as well as from the primary
adipocytes derived from WT mice (data not shown). We could
not rule out that a small level of TLR4 undetectable with this
method is present on their surface. Nonetheless, the endogenous
expression of FD and TLR4 at the mRNA level was present in
3T3L1 differentiated adipocytes (Figure 12). There was a clear
significant (p < 0.006) increase in the expression of FD in
differentiated 3T3L1 cells 48 h after stimulating with 10µg/ml
and 20µg/ml of recombinantMBL but only significant (p< 0.05)
decrease in TLR4 expression was seen with 10µg/ml not with
20µg/ml of recombinant MBL (Figures 12A,B). There was a
FIGURE 11 | Microscale thermophoresis showing biophysical analysis of
binding of human rMBL with human rTLR4/MD2. MST is based on the
detection of a temperature-induced change in fluorescence of rTLR4/MD2
(target) as a function of the concentration of a non-fluorescent ligand (rMBL).
By titrating MBL into the labeled TLR4 the Kd (dissociation constant) was
9.07 × E−07 indicating strong binding.
dose-dependent increase in the expression of FD in differentiated
3T3L1 cells (p< 0.05) treated with LPS (Figure 12C). In contrast,
a decreasing trend in the expression of TLR4 was seen in response
to the LPS (Figure 12D). A correlation (r = 0.51) between FD
and TLR4 expression in 3T3 cells in response to LPS (5µg/ml)
was noticed but it was not significant (Figures 12C,D). These
data indicate although TLR4 is undetectable by flow cytometry
on the surface of 3T3 cells but still it can bind to the MBL and its
ligand, LPS and modulate FD expression (Figures 12A,D). These
data suggest that MBL or LPS can bind to a common receptor
TLR4 to regulate the transcription of FD in adipocytes.
DISCUSSION
In this study, we report five main findings. First, we have
successfully generated GalNAc-conjugated siRNA duplexes of
MASP-1 and MASP-2, and these duplexes exhibit a low IC50
for liver-targeted delivery. Second, these duplexes specifically
targeted liver MASP-1 and MASP-2 genes and robustly silence
their expression in the liver, leading to systemic depletion of
these proteins. Our data confirm that MASP-1 and MASP-2
proteases are generated by the liver and consequently there is
little extrahepatic generation of these proteases to effect disease
phenotype locally in the joints. Furthermore, targeting of MASP-
2 expression inhibited C4b deposition on mannan and therefore
functionally inhibited the LP. Third, there was no significant
effect of MASP-1 inhibition on CAIA in mice, whereas silencing
of MASP-2 via RNAi inhibition partially attenuated arthritis in
mice. Four, MASP-1 andMASP-2may control the AP, possibly by
regulating along with MBL the transcription of FD under normal
physiological conditions. Finally, our MST data shows that MBL
directly interact with TLR4, consistent with the observations of
previous laboratories (67, 68).
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FIGURE 12 | Effect of human rMBL or human rTLR4 on FD expression on differentiated 3T3-L1 cells at 48 h. (A) rMBL increased FD expression in a dose-dependent
manner. (B) rMBL also effected the TLR4 expression. (C) LPS also increased FD expression dose-dependent manner. (D) LPS also decreased TLR4 expression with
increasing doses. Data are shown as Mean ± SEM of three replicative experiments. *p < 0.05 considered significant.
The role of MASP-1 and MASP-2 proteases in arthritis has
been unknown. The most abundant MASP in serum is MASP-1
(69, 70). MASP-1 has been shown to be predominately generated
by the liver (36, 38, 71, 72), and it can, therefore, be targeted
by RNAi using GalNAc-conjugated siRNAs due to the specific
affinity of GalNAc for ASPGR (27, 36, 57). We found that
MASP-1 silencing by RNAi had no significant effect on CAIA
even with more than 95% silencing at the transcriptional level
(in liver) as well as reduction in protein levels (in circulation;
Figures 3, 7, 4B). As this gene also produces MASP-3, which
is important in the induction of CAIA (40), any effect of
this targeting in MASP-3 was not sufficient to affect disease
generation. The minor non-significant decrease we have seen
might be due to the inhibition of LPS-induced AP by MASP-1
inhibition. If so then it will be consistent with recently published
studies showing an unexpected link between the LP and AP (46).
We asked the question: why there was no significant decrease
in the disease activity even by >95% inhibition of MASP-1
protease systemically? This might be related to difference in
the importance of MASP-1 for the AP in in vitro and in vivo
situations. Moreover, disease is dependent on the dose of anti-
CII abs but not LPS (13) for LPS injected mice do not develop
arthritis, but even if they do it is mild and transient lasting for
couple of days (13). CAIA is dependent on the AP (61) and mice
lacking C3, FB and FD were somewhat resistance to CAIA (40,
60, 61). Mice lacking MASP-1/3, i.e., lacking both MASP-1 and
MASP-3 were also resistance to CAIA (40). The synergistic role
of MASP-1 and MASP-2 in RA can’t be ruled out, since MASP-
1 activates MASP-2 to activate the LP (29). The above mentioned
small, non-significant decrease due toMASP-1 silencing in CAIA
we have seenmight also be due to the delayed activation of the LP
MASP-2 by inhibiting MASP-1 for MASP-2 plays an important
role to activate the AP via C4 bypass mechanism (62). We have
not tested the role ofMASP-1 in zymosan-induced arthritis (ZIA)
and one can draw inferences that these mice will not be protected
based on the above study (46). Furthermore, serum naturally
have antibodies to yeast so it can complicate the interpretation
by activation antibody-dependent mechanisms such as the CP.
CAIA is dependent not only on the AP but also on generation
of C5a. Normally the AP contribute 80–95% of complement
activation (73). Mice lacking C5 or treated with GalNAc-C5-
siRNA or anti-C5 inhibitory antibody do not develop arthritis
(15, 16, 74) despite the presence of MASP-1 and MASP-2. We
also found no effect of MASP-1 and MASP-2 silencing on the
expression of C5 in the liver (Figure 8H). These data confirm
that MASP-1 and MASP-2 inhibition have no effect on the liver
expression of downstream complement components, which are
essential for the precipitation of disease in the joints. As MASP-1
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or MASP-2 is knocked down, the effect of LPS on IL-1β is
blunted. As MASP-1 and MASP2 is knocked down, the effect of
LPS on IL-1β is completely blocked, indicating that the MASPs
are also important for the inflammatory response against LPS.
Again, these cytokines data are consistent with CDA in mice
treated with MASP-1 or MASP-2 siRNAs (Figure 3A).
Here, we found that nearly complete silencing of MASP-
2 expression by RNAi in the liver using GalNAc-MASP-
2-siRNA leads to a partial but significant decrease in the
CDA (Figure 3A). These results were consistent with our
previous study in which mice lacking MASP-2/sMAp were
also partially protected from CAIA (62). Interestingly, we have
generated the same phenotype in WT mice as seen in MASP-
2/sMAp−/− mice by injecting GalNAc-MASP-2-siRNA duplex,
i.e., nearly complete elimination of MASP-2/sMAp proteins
in the circulation (Figure 5B). In this study we could not
differentiate between the effects of MASP-2 and sMAp since
we have silenced both and the function of sMAp is unknown.
The duplex of GalNAc-MASP-2 silenced both MASP-2 and
sMAp, therefore, created an identical phenotype to the MASP-
2/sMAp−/− mice (Figures 5A,B). Thus, liver-targeted inhibition
of MASP-2 might be beneficial clinically to treat many ischemia
reperfusion injuries (IRI) due to their dependency onMASP-2. In
fact, MASP-2 has been shown to play an important role in many
IRI mouse models such as myocardial infarction, gastrointestinal
IRI, and cerebral IRI because mice lacking MBL or MASP-2
were protected but not mice lacking C4 (75). In these studies
it has been shown that MASP-2-dependent C4 bypass pathway
activated the AP and played an important role in IRI (75). But
none of these studies, have explored the mechanism(s) that leads
to MASP-2-dependent C4-bypass activation of the AP and which
component of the AP is involved or regulated? One study has
shown that MASP-2 can directly cleave C3 without involvement
of C4 or C2 (30) but still it is not enough to perpetuate AP
activation. Here we report for the first time that MASP-2 might
directly regulate the AP by further regulating the transcription
of FD in adipose tissue to generate a feedback loop for FD. FD
is predominately generated by adipocytes (38, 40), and adipose
tissue is present in or around all vital organs of the body including
liver and joints (data not shown). Mice lacking fat or FD have
defective AP (76) identical toMASP-1/3−/− mice orMASP-3−/−
mice (40, 41). Moreover, mice lacking FD or MBL A/C/FD−/−
mice are totally resistance to arthritis (59).
To further explore mechanisms by whichMASP-1 andMASP-
2 regulate the transcription of FD, we found that during
homeostasis there was a significant decrease of 72% in the
expression FD in the liver of mice injected simultaneously
with GalNac-MASP-1 plus GalNac-MASP-2 duplexes vs. singly
injected mice (Figure 8F). Interestingly, with this combined
treatment, there was no effect on expression of C3, FB, and
C5 in the liver (Figures 8D,E,H). No decrease in Properdin
expression was seen with combined silencing of MASP-1 and
FIGURE 13 | A hypothetical model in mouse showing how MBL or conjugates of MBL-MASP-1 or MBL-MASP-2 can regulate the transcription of FD to regulate the
activation of the AP via TLR4 receptors. Circulating MBL alone or MBL-MASP-1 or MBL-MASP-2 complexes can directly interact with disguised TLR4 on adipocytes
to activate the complement system via enhancing the expression of FD to regulate the AP pathway. (A) MBL or MBL-MASP-1 or MBL-MASP-2 conjugates under
normal physiological conditions can bind to the TLR4 and regulate the expression of FD but MASP-2 might be dominant. (B) In contrast, under inflammatory
conditions, MBL or MBL-MASP-1 or MBL-MASP-2 conjugates might be displaced by the LPS and modulate the transcription of FD through TLR4 receptors.
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MASP-2 (Figure 8G). Properdin is known to stabilize AP-C3
convertase, indicating that MASP-1 and MASP-2 contributes the
AP by sustaining the expression of both FD and properdin.
Overall these data showed that the conjugates of both MBL-
MASP-1 and MBL- MASP-2 might be directly regulating the
transcription of FD. Our in vivo data show that MASP-1
and 2 regulate FD transcription under normal physiological
conditions but not under inflammatory conditions (Figure 8F).
An inflammatory conditions in these mice were confirmed
by measure of IL-1β and TNF-α in the liver subsequently
after silencing of MASP-1 and MASP-2 and LPS injection
(Figures 9A,B). We hypothesize that regulation of transcription
of FD is switched under inflammatory conditions from MASP-
1 and MASP-2 to something else, such as LPS. LPS is a
ligand for TLR4 receptors and also competes with MBL for
its binding with TLR4 (67, 68). Thus, circulating complexes
of MBL-MASP-1 or MBL-MASP-2 or MBL might be replaced
with LPS while transitioning from normal to inflammatory
conditions. MBL, a prototypical pattern recognition molecule
can also modify the inflammatory response during bacterial
and viral infections. MBL could suppress LPS-induced TNF-
α and IL-12 production in THP-1 cells and monocyte-derived
dendritic cells by inhibiting LPS-induced NF-kB DNA binding
and translocation (68). We hypothesize that MBL-MASP-1 or
MASP-2 conjugates can control the transcription of FD in liver
under normal physiological conditions (Figure 13). A limitation
of our study is that we have not examined the expression of FD in
the liver ofMBL−/− andMASP-2−/− mice and this is due to the
non-availability of these mice from any commercial source at the
time these data were collected. We have also not used complexes
ofMBL-MASP-1 orMBL-MASP-2 due to the autocatalytic nature
of these enzymes. However, transient knockdown may provide
a more representative picture if the importance of MASP-2,
as these mice have not had the same opportunity to develop
compensatory mechanisms as ofMASP-2−/− mice.
We confirmed by MST a direct binding between human
recombinant MBL and human recombinant TLR4 with
an equilibrium dissociation constant (Kd) of 907.28 nM
concentration (Figure 11). To further provide the evidence that
interactions between MBL-MASPs and TLR4 can occur, in vivo,
we found primary adipocytes from mouse adipose tissue injected
with LPS have reasonably good expression of TLR4 but a huge
expression of FD (data not shown). Conversely, differentiated
3T3L1 cells, which develops adipocyte-like morphology, have
high levels of TLR4 but low levels of FD expression (Figure 12).
Interestingly, in these differentiated 3T3 cells, with MBL or
LPS treatment, TLR4 expression decreases but FD expression
increases (Figure 12) again suggesting a link between LPS, TLR4,
and FD transcription (Figure 13).
Overall, in this study, we have generated highly potent
and specific MASP-1 and MASP-2 siRNA duplexes, especially
targeting liver for a longer time with an excellent clinical
therapeutic potential. These duplexes can be tested further in
various mouse models of diseases involving MASP-1 and MASP-
2 such as IgA Nephropathy (77) and experimental pneumococcal
meningitis (78) to understand the contribution of liver MASP1
and MASP2 to disease pathology in conditions where LP
activations has been implicated. Humanized MASP-2 duplexes
can also be developed and tested. We think that our MASP-2
siRNA duplexes present another therapeutic option not only for
arthritis but for above mentioned diseases and it will be worth to
explore further.
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